- Boehringer Ingelheim’s Animal Health business generated €2.6 billion in first-half 2026 sales, a 0.4% increase year over year.
- The company cited increased consumer price sensitivity and fewer veterinary visits in several markets.
- Recent launches include the LENZELTA® mastitis vaccine for dairy cattle and the Eko Vet+™ | CANINEBEAT® AI heart murmur detection platform for dogs.
- Boehringer Ingelheim also continues supporting the U.S. response to New World screwworm following Emergency Use Authorizations granted earlier this year.
Boehringer Ingelheim reported €2.6 billion in Animal Health sales during the first half of 2026, representing a 0.4% year-over-year increase as the company continued rolling out new products despite softer market conditions.
According to the company, performance reflected a modestly growing animal health market, with increased consumer price sensitivity and fewer veterinary visits reported in several countries.
Among the company’s recent launches is LENZELTA®, a vaccine designed to help prevent mastitis in dairy cows that is now available in several European Union markets. Boehringer Ingelheim also expanded the availability of Eko Vet+™ | CANINEBEAT® AI, an artificial intelligence-powered tool that assists veterinarians in detecting heart murmurs in dogs. The technology has launched in the United States, the United Kingdom and Germany.
The company also said it continues to support responses to emerging animal disease threats, including New World screwworm in the United States, following Emergency Use Authorizations issued by the U.S. Food and Drug Administration earlier this year.
Looking ahead, Boehringer Ingelheim said its Animal Health research and development pipeline includes candidates targeting infectious diseases, non-infectious conditions and parasiticides across companion animals, equine and livestock species.
Information sourced from a Boehringer Ingelheim financial results release.
